Status:
Concluded with an LOI
Manufacturer:
Hoffmann-La Roche Ltd.
Indication:
Neovascular (Wet) Age-related Macular Degeneration (nAMD)
Last updated April 27, 2023
Status:
Concluded with an LOI
Manufacturer:
Alnylam Netherlands B.V.
Indication:
Acute Hepatic Porphyria
Last updated April 27, 2023
Firdapse (amifampridine phosphate)
Status:
Concluded with an LOI
Manufacturer:
KYE Pharmaceuticals Inc.
Indication:
Lambert-Eaton Myasthenic Syndrome (LEMS)
Last updated April 25, 2023
Status:
Concluded without agreement
Manufacturer:
Duchesnay Inc.
Indication:
Dyspareunia and/or Vaginal Dryness
Last updated April 14, 2023
Status:
Concluded without agreement
Manufacturer:
Lupin Pharma Canada Ltd.
Indication:
Postmenopausal vulvovaginal atrophy
Last updated April 14, 2023
Status:
Concluded with an LOI
Manufacturer:
Novartis Pharmaceuticals Canada Inc.
Indication:
Diabetic Macular Edema
Last updated April 11, 2023
Status:
Concluded with an LOI
Manufacturer:
Sanofi-Aventis Canada Inc.
Indication:
Atopic dermatitis
Last updated April 4, 2023
Status:
Concluded with an LOI
Manufacturer:
Eli Lilly Canada Inc.
Indication:
Medullary thyroid cancer (MTC), rearranged during transfection (RET)-mutant, in adult and pediatric patients 12 years of age and older with unresectable advanced or metastatic disease
Last updated March 31, 2023
Status:
Concluded with an LOI
Manufacturer:
Eli Lilly Canada Inc.
Indication:
Differentiated thyroid carcinoma (DTC), Rearranged during transfection (RET) fusion-positive, in adult patients with advanced or metastatic disease (not amenable to surgery or radioactive iodine therapy) monotherapy treatment following prior treatment with sorafenib and/or lenvatinib
Last updated March 31, 2023
Status:
Concluded with an LOI
Manufacturer:
Eli Lilly Canada Inc.
Indication:
Metastatic RET fusion-positive non-small cell lung cancer (NSCLC), Monotherapy for the treatment of adult patients
Last updated March 31, 2023